Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.47 |
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889739 | 0.83 | RPS6KA5 (0.45) | P2RX7RPS6KA5METMEN1HPGD | |
| SCHEMBL3225487 | 0.77 | SLC6A2 (0.43) | P2RX7RPS6KA5METMEN1HPGD | |
| SCHEMBL3227906 | 0.77 | SLC6A2 (0.43) | P2RX7RPS6KA5METMEN1HPGD | |
| SCHEMBL5865198 | 0.77 | MEN1 (0.69) | P2RX7MEN1HPGDKMT2AHSD17B10 | |
| SCHEMBL28575649 | 0.77 | RPS6KA5 (0.52) | RPS6KA5METRPS6KA4CDC7CDK2 | |
| SCHEMBL4546571 | 0.77 | RPS6KA5 (0.52) | RPS6KA5METMEN1HPGDKMT2A | |
| SCHEMBL3218825 | 0.74 | SLC6A2 (0.66) | — | |
| SCHEMBL3225255 | 0.74 | SLC6A2 (0.66) | — | |
| SCHEMBL22930553 | 0.74 | RPS6KA5 (0.49) | RPS6KA5METMEN1HPGDKMT2A | |
| SCHEMBL2586507 | 0.72 | P2RX7 (0.50) | P2RX7CYP19A1CDC7CDK2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | XENON PHARMACEUTICALS INC. (CA) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269788-A1 | SPIRO-OXINDOLE-DERIVATIVES AS SODIUM CHANNEL BLOCKERS | SCN3A, SCN1B, SCN2B | P2RX7 600/4885RPS6KA5 2498/4885MET 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.